CGC 729
Alternative Names: CGC-729Latest Information Update: 29 May 2024
At a glance
- Originator CureGenetics
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 23 May 2024 Interim pharmacokinetics, efficacy and adverse events data from a phase-I trial in Solid tumours released by CureGenetics
- 11 Apr 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral) (NCT06394622)
- 24 Jul 2023 Preclinical trials in Solid tumours in China (Parenteral), prior to July 2023 (Cure Genetics pipeline, July 2023)